Intrinsic Subtype Switching and Acquired <i>ERBB2</i>/<i>HER2</i> Amplifications and Mutations in Breast Cancer Brain Metastases

Abstract

Breast cancer BrM commonly acquire alterations in clinically actionable genes, with metastasis-acquired ERBB2/HER2 alterations in approximately 20% of ERBB2/HER2-negative cases. These observations have immediate clinical implications for patients with ERBB2/HER2-negative breast cancer and support comprehensive profiling of metastases to inform clinical care.